- PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
- PROFESSOR | Pharmacological Sciences
- PROFESSOR | Geriatrics and Palliative Medicine
- Endocrinology, Diabetes and Metabolism
- Hospital Affiliation
- The Mount Sinai Hospital
- Dual Energy X-Ray Absorptiometry
- Osteogenesis Imperfecta
- Paget's Disease of Bone
- Vitamin D Deficiency
Bone Biology, Bone Metabolism, Cell Biology, Cytokines, Developmental Biology, Gene Expressions, Genetics, Hormones, Immunosuppression, Macrophage, Microarray, Molecular Biology, Neuromodulation, Osteoporosis, Signal Transduction, Skeletal Biology, Thyroid, Transcription Factors
Multi-Disciplinary Training Area
Developmental and Stem Cell Biology [DSCB]
PHD, Royal Postgraduate Medical School
MBBS, King George's Medical College
MD, University of London
Royal Postgraduate Medical School
Sreebny Distinguished Lecture,
State University of New York, Stony Brook,
Honorary Doctor of Medicine (Laurea Honoris Causa),
University of Bari
The Marookian Lecture
University of Pennsylvania
Sibte H. Zaidi Memorial Oration
Indian Institute of Toxicology Research, India
Kramer Visiting Professor
Dartmouth Medical School
Scientific Director and Chair
New York Skeletal Biology and Medicine Conferences Highlight Speaker, NIA Council
Japanese Bone and Mineral society
Japan Bone Forum
Association of American Physicians
Cambridge Philosophical Society
Co-Chair, Orgainzing Committee
National Scientific Advisory Council & Research Committee
American Federation for Aging Research
Department of Veterans Affairs Medical Research Advisory Group
Department of Veterans Affairs Merit Review Council
American Society for Clinical Investigation
University of Cambridge
Royal College of Pathologists
Institute of Biologists of England
Tata Memorial Scholar, London
Nuffield Award for Science Lecturer, London
Stott Gold Medal in Pathology
King George's Medical College, Lucknow, India
Sir Edmund Davis Scholarship
University of London
Royal College of Physicians
Dubin 1994, London 1997
Department of Veterans Affairs Endocrine Merit Review Committee
Chair 2000, 2003-2006, Member 1997-2000
Association of Osteobiology, Interurban Clinical Club, Councilor
2004, 2005, & 2010
Research Excellence Award - Department of Veterans Affairs
NIH Orthopedics and Musculoskeletal Study Section
Chair 2002-2003, Member 1998-2003
Mone Zaidi has made seminal contributions to the pathogenesis and therapy of osteoporosis, a devastating public health hazard. These include the first description of extracellular calcium sensing by the osteoclast; evidence that nuclear calcium in bone cells is tightly regulated by ryanodine receptors; and the discovery that nitric oxide controls osteoclast function. More recently, he established the concept of a pituitary-bone axis, in which the pituitary hormones FSH, TSH, ACTH and oxytocin directly regulate the skeleton. The idea that low TSH contributes to the osteoporosis of thyroid disorders has led to revised criteria that mandate less aggressive TSH suppression. Similarly, the rapid late peri-menopausal bone loss, which is now partly attributable to a rising FSH, has prompted new guidelines for early evaluation of women. The finding that ACTH attenuates avascular necrosis of the hip will likewise help prevent this crippling complication of long-term steroid use. Finally, Dr. Zaidi has proven that the inhibition of calcineurin in the osteoblast by the widely used immunosuppressant drugs cyclosporine and tacrolimus underlies the acute, rapid, and severe bone loss in transplant patients. These observations have thus created new paradigms for understanding and treating osteoporosis. Importantly, Dr. Zaidi has chaired several standing study sections, and has conceptualized and runs one of the most revered international conferences in skeletal biology and medicine.
Zaidi M, Sun L, Robinson LJ, Tourkova IL, Liu L, Wang Y, Zhu LL, Liu X, Liu JH, Peng YZ, Yang G, Sun H, Levine A, Iqbal J, Yaroslavskiy BB, Isales C, Blair HC, . ACTH protects against glucocorticoid-induced osteonecrosis of bone. Proceedings of the National Academy of Science 2010;(107): 8782-8787.
Iqbal J, Sun L, Zaidi M. Coupling bone degradation and formation.. Nature Medicine 2009;(15): 729-731.
Tamma R, Colaianni G, Zhu LL, DiBenedetto A, Greco G, Montemurro G, Patano N, Strippoli M, Vergari R, Mancini L, Colucci S, Grano MM, Faccio R, Liu X, Li J, Usmani S, Nishimori K, Young L, Bachar M, Bab I, Buettner C, Iqbal J, Sun L, Zaidi M, Zallone A. Oxytocin is an anabolic bone hormone.. Proceeding of the national Academy of Science 2008;(106): 7149-7154.
Sun L, Vukicevic S, Baliram A, Yang G, Sendak R, McPherson J, Zhu LL, Iqbal J, Latif R, Natrajan A, Arabi A, Yamoah KO, Moonga BS, Gabet Y, Davies TF, Bab I, Abe E, Sampath K, Zaidi M, , . Intermittent recombinant TSH injection prevents ovariectomy-induced bone loss.. Proceedings of the national Academy of Sciences 2008;(105): 4289-4294.
Zaidi M. Skeletal remodeling in health and disease. Nature Medicine 2007;(13): 791-801.
Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M. FSH stimulates TNF production from immune cells to trigger osteoclast and osteoblast formation.. Proceedings of the National Academy of Sciences;(103): 14925-14930.
Hase H, Ando T, Eldeiry L, Brebene A, Peng Y, Lin L, Amano H, Davies TF, Sun L, Zaidi M, Abe E. TNF mediates the skeletal effects of TSH. Proceedings of the National Academy of Sciences;(103): 12849-12854.
Sun L, Zhang Z, Iqbal J, Zaidi S, Papachristou DJ, Zhou H, Sharrow AC, Peng Y, Yaroslavskiy BB, Zhu LL, Zallone A, Sairam MR, Kumar TR, Landa LC, Schaffler MB, Moonga BS, Blair HC, Zaidi M. FSH directly regulates bone mass.. Cell 2006;(125): 247-260.
Sun L, Blair HC, Peng Y, Zaidi N, Adebanjo OA, Wu XB, Wu XY, Iqbal J, Epstein S, Abe E, Moonga BS, Zaidi M. Calcineurin regulates bone formation by the osteoblast.. Proceedings of the National Academy of Sciences 2005;(47): 17130-17135.
Abe E, Marians R, Wu XB, Iqbal J, Ando T, Blair HC, Davies TF, Zaidi M. TSH is a negative regulator of bone remodelling.. Cell;(175): 151-162.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Zaidi during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- F. Hoffman-La Roche Ltd.
- Genzyme Corporation
- Gerson Lehrman Group
- Merck & Co., Inc.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Takeda Pharmaceuticals International GmbH
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.